Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × mCRPC × 30 days × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 8 Parkinson Disease 4, Autosomal Dominant Lewy Body 5 Hematologic Neoplasms 5 Breast Neoplasms 5 Melanoma 4 Ovarian Neoplasms 3 Carcinoma, Renal Cell 3 Uterine Cervical Neoplasms 2 Urinary Bladder Neoplasms 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Neuroendocrine Tumors 2 Neoplasm Metastasis 2 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Lymphoma, Mantle-Cell 2 Leukemia, Myeloid, Acute 2 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Adenoma, Islet Cell 2 von Hippel-Lindau Disease 1 mCRPC 1 Various Advanced Cancer 1 Uveal Melanoma 1 Urothelial Cancer 1 Thyroid Cancer, Papillary 1 Solid Tumors 1 Smoldering Multiple Myeloma 1 Small Cell Lung Carcinoma 1 Skin Neoplasms 1 Skin Diseases 1

Interventions

talazoparib 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03395197 2026-03-12

TALAPRO-2

Pfizer

Phase 3 Active not recruiting

1,054 enrolled 21 charts 1 FDA

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡